Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Lymphoid 1Gastrointestinal 1Dermatologic 1CNS 1

Conditions

Neoplasms 19Endometrial Neoplasms 15Ovarian Neoplasms 11Carcinoma, Non-Small-Cell Lung 10Neoplasm Metastasis 7Squamous Cell Carcinoma of Head and Neck 6Uterine Cervical Neoplasms 5Head and Neck Neoplasms 5Breast Neoplasms 5Rectal Neoplasms 4Pancreatic Neoplasms 4Melanoma 4Lung Neoplasms 4Colonic Neoplasms 4Fallopian Tube Neoplasms 3Colorectal Neoplasms 3Triple Negative Breast Neoplasms 2Stomach Neoplasms 2Recurrence 2Osteosarcoma 2Multiple Myeloma 2Locally Advanced Rectal Cancer (LARC) 2Carcinoma, Renal Cell 2Carcinoma, Neuroendocrine 2Carcinoma, Hepatocellular 2Carcinoma 2Vulvar Neoplasms 1Vaginal Neoplasms 1Uterine Neoplasms 1Turcot syndrome 1

Interventions

Vincristine 25Cyclophosphamide 25Irinotecan 21Temozolomide 18Doxorubicin 16Radiotherapy 15Filgrastim 15Ifosfamide 14Dactinomycin 14Etoposide 11Vinorelbine 9Melphalan 9Magnetic Resonance Spectroscopy 9Granulocyte Colony-Stimulating Factor 9Radiation 8pegfilgrastim 7X-Rays 7Specimen Handling 7Sirolimus 7Topotecan 6Phantoms, Imaging 6Peripheral Blood Stem Cell Transplantation 6Gemcitabine 6cixutumumab 5Busulfan 5Biopsy 5temsirolimus 4irinotecan sucrosofate 4fludarabine 4etoposide phosphate 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Rhabdomyosarcoma × dostarlimab × Clear all
NCT06521567 2025-11-12

A Study of Cobolimab Plus Dostarlimab in Pediatric and Young Adult Participants With Cancer

GlaxoSmithKline

Phase 1/2 Active not recruiting
83 enrolled
CNSDermatologicGastrointestinalLymphoidSarcoma

Fibrolamellar hepatocellular carcinoma, Diffuse Intrinsic Pontine Glioma, Ependymoma, Glioblastoma, Carcinoma, Hepatocellular, Hodgkin Disease, Melanoma, Rhabdomyosarcoma, Osteosarcoma, Hepatoblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡